Archimedes Raises £65 million for Leap to U.S.
This article was originally published in Start Up
Executive Summary
About a year after Novo A/S announced the launch of its Growth Equity Fund, the firm has found a home for its first significant investment, contributing £40 million of a £65 million ($100 million) round for privately-owned UK-based specialty pharma firm Archimedes Pharma. Participants describe this as the largest private European biopharma fundraising in the last 15 years.
You may also be interested in...
Can New Pain Drugs Break Through To A Growing Cancer Market and Beyond?
Two new drug approvals represent the latest innovations in the emerging area of breakthrough cancer pain, designed to ease intense, short-term waves of heightened suffering in patients who are already taking opioids for persistent background pain.
Can New Pain Drugs Break Through To A Growing Cancer Market and Beyond?
Two new drug approvals represent the latest innovations in the emerging area of breakthrough cancer pain, designed to ease intense, short-term waves of heightened suffering in patients who are already taking opioids for persistent background pain.
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?